A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 175-181

  Schaich, M ^a   Kestel, L ^a   Pfirrmann, M ^b   Robel, K ^a   Illmer, T ^a   Kramer, M ^a   Dill, C ^a   Ehninger, G ^a   Schackert, G ^a   Krex, Dietmar ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Glioblastoma; MDR1; MGMT; Polymorphism; Temozolomide

Indexed keywords

MESSENGER RNA; METHYL TETRAZOLIUM; MULTIDRUG RESISTANCE PROTEIN 1; TEMOZOLOMIDE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; EXON; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 58949089716     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn548     Document Type: Article

References (30)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005; 109: 93-108.
2. Mathieu D, Fortin D. The role of chemotherapy in the treatment of malignant astrocytomas. Can J Neurol Sci 2006; 33: 127-140.
3. Newlands ES, Stevens MF, Wedge SR et al. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
4. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-266.
5. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
6. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
7. Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6- alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998; 16: 3851-3857.
8. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
9. Esteller M, Hamilton SR, Burger PC et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-797.
10. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
11. Ambudkar SV, Dey S, Hrycyna CA et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
12. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
13. Jelinek J, Rafferty JA, Cmejla R et al. A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Ther 1999; 6: 1489-1493.
14. Demeule M, Shedid D, Beaulieu E et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer 2001; 93: 62-66.
15. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478.
16. Hitzl M, Drescher S, van der KH et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293-298.
17. Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21: 904-913.
18. Illmer T, Schuler US, Thiede C et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955-4962.
19. Illmer T, Schaich M, Oelschlagel U et al. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples. Leuk Res 1999; 23: 653-663.
20. Chen CJ, Clark D, Ueda K et al. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990; 265: 506-514.
21. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
22. Schiedlmeier B, Kuhlcke K, Eckert HG et al. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 2000; 95: 1237-1248.
23. Kreuzer KA, Lass U, Bohn A et al. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 1999; 59: 3171-3174.
24. Mollemann M, Wolter M, Felsberg J et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005; 113: 379-385.
25. Toth K, Vaughan MM, Peress NS et al. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 1996; 149: 853-858.
26. Sawada T, Kato Y, Sakayori N et al. Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors. Brain Tumor Pathol 1999; 16: 23-27.
27. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-199.
28. Miller KL, Kelsey KT, Wiencke JK et al. The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology 2005; 25: 85-90.
29. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
30. Martinez R, Schackert HK, Plaschke J et al. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 2004; 66: 395-403.